We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis
News

Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis

Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis
News

Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ModiQuest B.V. has announced that it has discovered the cellular mechanism of action of its therapeutic anti-citrullinated protein lead antibodies (tACPA) for the treatment of rheumatoid arthritis (RA) and other diseases.

To accelerate tACPA development towards clinical Proof of Concept, facilitate funding, and attract a development partner, Citryll B.V. was founded as a single asset drug development company.

The tACPAs are active in different validated RA animal models and models for other human diseases. They exert their therapeutic effect by inhibiting the formation of Neutrophil extracellular traps (NETs) as shown with primary human neutrophils. NETs are extracellular lattices of decondensed chromatin decorated with antimicrobial factors, whose function is to eliminate invading microorganisms.

Dysregulated NETosis constitutes a pathogenic mechanism in autoimmune and sterile inflammatory diseases. This offers novel therapeutic opportunities for diseases with unmet medical needs, including RA, where existing treatments can have serious side-effects and comprise a significant percentage of non-responders. NETosis is peptidyl arginine deiminase (PAD) dependent, creating neo-epitopes that trigger autoimmunity and breaking of tolerance in RA.

ModiQuest has discovered tACPAs using its proprietary antibody generation technology platforms ModiFuse™ (highly efficient hybridoma electrofusion technology), ModiSelect™ (B cell selection technology for low immunogenic or multiple antigen targets) and ModiPhage™ (proprietary phage display libraries).

All three technology platforms are also used by ModiQuest’s service business, ModiQuest Research B.V., for custom antibody lead generation in third party service projects with a recent addition of an innovative platform for difficult antibody drug targets, ModiVacc™.

Advertisement